Immunocore Holdings PLC

Immunocore Holdings plc announced that all ten resolutions presented at its 2026 Annual General Meeting of Shareholders on May 27, 2026, were duly passed by shareholders.

Immunocore Holdings plc announced first quarter 2026 financial results, highlighting a 14% year-over-year increase in KIMMTRAK net sales to $106.7 million and positive five-year survival data.

Immunocore Holdings plc announced robust fourth quarter and full year 2025 financial results, driven by strong KIMMTRAK sales and significant progress across its oncology, infectious disease, and autoimmune pipelines.

Immunocore Holdings plc announced the resignation of its Head of Research & Development, David Berman, effective February 27, 2026, with the company opting to streamline its existing R&D structure.

Immunocore Holdings plc announced its 2026 strategic priorities, highlighted by clinical trial advancements across oncology, infectious, and autoimmune diseases, alongside a preliminary year-end 2025 cash position of $864 million.

Immunocore Holdings plc announced the immediate resignation of a board member and the future departure of its Chief Human Resources Officer.

Immunocore Holdings plc announced its first-quarter 2026 financial results, showcasing a 13.6% increase in total revenue driven by strong sales of its lead therapy, KIMMTRAK.

Immunocore Holdings plc reported strong 29.2% Q3 revenue growth from KIMMTRAK sales, alongside increased R&D investment and a net loss, as its pipeline progresses.

Immunocore Holdings plc announced significant revenue growth for its lead product KIMMTRAK and a substantial reduction in net loss for the second quarter and first half of 2025, driven by increased sales volume and global expansion.

Immunocore Holdings plc announces a 33% increase in revenue to $93.9 million for the first quarter of 2025, driven by strong sales of KIMMTRAK.

Immunocore Holdings reported a net income of $8.7 million for the third quarter of 2024, driven by a 28.1% increase in product revenue from KIMMTRAK sales.

Immunocore Holdings reported a 32.3% increase in product revenue for the second quarter of 2024, driven by sales of KIMMTRAK and progress in its clinical pipeline.

Immunocore Holdings plc announced significant revenue growth for 2025, driven by its lead product KIMMTRAK, while also reducing its net loss, signaling progress in its commercialization and pipeline development.

Immunocore Holdings plc announces its 2024 financial results, highlighting KIMMTRAK's commercial progress and outlining strategic priorities for 2025, including expanding its melanoma franchise and advancing its clinical portfolio.

Immunocore Holdings plc, a commercial-stage biotechnology company, released its full year 2023 results, showcasing revenue growth from KIMMTRAK and advancements in its ImmTAX platform.

Director Peter John Ratcliffe was granted 27,492 share options in Immunocore Holdings plc.

Director Kristine Peterson was granted 27,492 stock options in Immunocore Holdings plc as part of a standard equity incentive.

Director William Pao was granted 27,492 stock options in Immunocore Holdings plc with an exercise price of $28.52.

Director Siddharth Kaul was granted 27,492 stock options in Immunocore Holdings plc as part of an equity compensation award.

Director Roy Herbst was granted 27,492 stock options in Immunocore Holdings plc as part of an equity compensation award.

Immunocore Holdings plc director John Irving Bell was granted 27,492 stock options as part of a standard equity compensation award.

Immunocore Holdings plc has issued its proxy statement for the 2026 Annual General Meeting to be held on May 27, 2026.

Immunocore Holdings announces its 2025 Annual General Meeting (AGM) to be held on May 15, 2025, seeking shareholder votes on director re-appointments, executive compensation, auditor ratification, and share issuance authorizations.

Immunocore Holdings announces its 2024 Annual General Meeting (AGM) to be held on May 23, 2024, featuring proposals for director re-appointments, executive compensation approval, auditor ratification, and adoption of new articles of association.

Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 5.5% beneficial ownership stake in Immunocore Holdings plc.

T. Rowe Price Investment Management, Inc. has reported an updated beneficial ownership of 6.0% in ImmunoCore Holdings PLC-ADR, holding 3,041,904 shares.

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have reported a 5.6% beneficial ownership stake in Immunocore Holdings plc.

Tang Capital Management and Kevin Tang reported a combined beneficial ownership of 5.2% in Immunocore Holdings plc, totaling 2,605,608 American Depositary Shares.

Eli Lilly and its subsidiary, Eli Lilly S.A., have reported zero beneficial ownership in Immunocore Holdings plc, indicating a complete divestment of their previous stake.

PRIMECAP Management Co. reports an increased beneficial ownership of 7.51% in Immunocore Holdings plc ADRs.